Post-Conference Perspectives: 2022 San Antonio Breast Cancer Symposium Highlights

Charles E. Geyer, MD and Ian E. Krop, MD, PhD provide an overview of the current breast cancer treatment landscape, with a focus on the management of patients with ER+/HER2- metastatic breast cancer.

Two breast cancer experts review updates from the SOFT and TAILORx trials and discuss racial disparities in breast cancer treatment and clinical trials.

Dr Geyer and Dr Krop explore data from the OlympiA phase III trial of adjuvant olaparib in patients with variants in BRCA1/2.

Conversation centered around the clinical implications of recently presented data from the randomized, multi-dose phase II SERENA-2 trial.

Charles E. Geyer, MD and Ian E. Krop, MD, PhD touch on recent advances in the metastatic HR+ breast cancer setting and evaluate PROTAC estrogen receptor (ER) degraders compared with other ER modulators.

Dr Krop leads a discussion of results from the DESTINY-Breast02 and DESTINY-Breast03 studies concerning the use of trastuzumab deruxtecan in patients with metastatic breast cancer.

Breast cancer experts exchange thoughts on the treatment of HER2+ breast cancer with CNS involvement, particularly the use of trastuzumab deruxtecan in this subset of patients.

Dr Geyer and Dr Krop discuss key data and the evolving standard of care for patients with HER2-low breast cancer.

Closing thoughts on the TALENT study concerning the use of neoadjuvant trastuzumab deruxtecan in patients with HER2-low, HR+ early-stage breast cancer.